Skip to main content

Advertisement

SpringerLink
Log in

Treatment of gastrointestinal acute graft-versus-host disease

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Therapy of acute graft-versus-host disease (GVHD) aims to selectively alter the grafthost interactions to foster antitumor effect and minimize antihost effects. The immunosuppression produced by the various therapies ranges from broad, nonselective effects to relatively narrow targeted impact. Despite advances in understanding the pathophysiology of GVHD, newer agents with more selective effects have not yet produced therapeutic advances. The newer targeted agents continue to produce a degree of immunosuppression in which infection and relapse of malignancy are all too common. High-dose systemic steroids remain, as they have for two decades, the initial treatment of choice. Patients failing to respond to steroids continue to represent a challenge, as no second-line therapy is clearly superior to the others. However, some of the new agents appear to be particularly effective in certain organs involved with acute GVHD. For those patients with steroid-refractory GVHD involving primarily the gut, we favor infliximab with concomitant antifungal therapy. For those with primarily skin or liver disease, we favor extracorporeal photochemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Tabbara IA, Zimmerman K, Morgan C, Nahleh Z: Allogenic hematopoietic stem cell transplantation. Arch Int Med 2002, 162: 1558–1566.

    Article  Google Scholar 

  2. Nash RA, Pepe MS, Storb R, et al.: Acute graft-versus-host disease: analysis of risk factors after allogenic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992, 80: 1838–1845.

    PubMed  CAS  Google Scholar 

  3. Przepiorka D, Smith TL, Folloder J, et al.: Risk factors for acute graft-versus-host disease after allogenic blood stem cell transplantation. Blood 1999, 94: 1465–1470.

    PubMed  CAS  Google Scholar 

  4. Vogelsang GB, Lee L, Bensen-Kennedy DM: Pathogenesis and treatment of graft-versus-host disease after bone marrow transplantation. Ann Rev Med 2003, 54: 29–52. A comprehensive review with a focus on pathogenesis.

    Article  PubMed  CAS  Google Scholar 

  5. Couriel D, Caldera H, Champlin R, Komanduri K: Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004, 101: 1936–1946. General overview of acute GVHD.

    Article  PubMed  Google Scholar 

  6. Akpek G, Chinratanalab W, Lee LA, et al.: Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transpl 2003, 9: 46–51.

    Article  Google Scholar 

  7. Ratanatharathorn V, Ayash L, Lazarus HM, et al.: Chronic graft-versus-host disease: clinical manifestations and therapy. Bone Marrow Transpl 2001, 28: 121–129.

    Article  CAS  Google Scholar 

  8. Higman MA, Vogelsang GB: Chronic graft-versus-host disease. Br J Haematol 2004, 125: 435–454.

    Article  PubMed  Google Scholar 

  9. Cutler C, Giri S, Jeyapalan S, et al.: Acute and chronic graft-versus-host disease after allogenic peripheral blood stem cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19: 3685–3691.

    PubMed  CAS  Google Scholar 

  10. Schmitz N, Beksac M, Hasenclever D, et al.: Transplantation of mobilized peripheral blood cells to HLAidentical siblings with standard risk leukemia. Blood 2002, 100: 761–767.

    Article  PubMed  CAS  Google Scholar 

  11. Champlin RE, Schmitz N, Horowitz MM, et al.: Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogenic transplantation. Blood 2000, 95: 3702–3709.

    PubMed  CAS  Google Scholar 

  12. Bacigalupo A, Palandri F: Management of acute graft versus host disease. Hematol J 2004, 5: 189–196.

    Article  PubMed  CAS  Google Scholar 

  13. Couriel DR, Saliba RM, Giralt S, et al.: Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogenic hematopoietic transplantation. Biol Blood Marrow Transpl 2004, 10: 178–185.

    Article  Google Scholar 

  14. Martin PJ, McDonald GB, Sanders JE, et al.: Increasingly frequent diagnosis of acute gastrointestinal graftversus-host disease after allogenic hematopoietic cell transplantation. Biol Blood Marrow Transpl 2004, 10: 320–327.

    Article  Google Scholar 

  15. Hill GR, Ferrara JLM: The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogenic bone marrow transplantation. Blood 2000, 95: 2754–2759.

    PubMed  CAS  Google Scholar 

  16. Przepiorka D, Weisdorf D, Martin P, et al.: Consensus conference on acute GVHD grading. Bone Marrow Transpl 1995, 15: 825–828.

    CAS  Google Scholar 

  17. Gratwohl A, Hermans J, Apperley J, et al.: Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood 1995, 86: 813–818.

    PubMed  CAS  Google Scholar 

  18. LeBlanc K, Ringden O, Remberger M: A low body mass index is correlated with poor survival after allogenic stem cell transplantation. Haematologica 2003, 88: 1044–1052.

    Google Scholar 

  19. Doherty J, Zahurak M, Margolis J, et al.: Chronic graft-versus-host disease and severe weight loss. Blood 1999, 94[Suppl 1]:A696.

    Google Scholar 

  20. Jacobsohn DA, Margolis J, Doherty J, et al.: Weight loss and malnutrition in patients with chronic graft-versushost disease. Bone Marrow Transpl 2002, 29: 231–236.

    Article  CAS  Google Scholar 

  21. Nash RA, Antin JH, Karanes C, et al.: Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 9: 2062–2068.

    Google Scholar 

  22. Martin PJ, Schoch G, Fisher L, et al.: A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76: 1464–1472.

    PubMed  CAS  Google Scholar 

  23. Hings JM, Severson R, Filipovich AH, et al.: Treatment of moderate and severe acute graft-versus-host disease after allogenic bone marrow transplantation. Transplant 1994, 58: 437–442.

    Article  CAS  Google Scholar 

  24. MacMillan ML, Weisdorf DJ, Wagner JE, et al.: Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transpl 2002, 8: 387–394.

    Article  CAS  Google Scholar 

  25. McDonald GB, Bouvier M, Hockenbery DM, et al.: Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastro 1998, 115: 28–35.

    Article  CAS  Google Scholar 

  26. Bertz H, Afting M, Kreisel W, et al.: Feasibility and response to busdesonide as topical corticosteroid therapy for acute intestinal graft-versus-host disease. Bone Marrow Transpl 1999, 24: 1185–1189.

    Article  CAS  Google Scholar 

  27. Hsu B, May R, Carrum G, et al.: Use of anti-thymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transpl 2001, 28: 945–950.

    Article  CAS  Google Scholar 

  28. Graziani F, Van Lint MT, Dominietto A, et al.: Treatment of acute graft-versus-host disease with low-dose, alternate day antithymocyte globulin. Haematologica 2002, 87: 973–978.

    PubMed  CAS  Google Scholar 

  29. Martin PJ, Schoch G, Fisher L, et al.: A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatments. Blood 1991, 77: 1821–1828.

    PubMed  CAS  Google Scholar 

  30. Antin JH, Chen AR, Couriel DR, et al.: Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transpl 2004, 10: 655–668. Recent review of various therapies for steroid-refractory disease.

    Article  CAS  Google Scholar 

  31. MacMillan ML, Weisdorf DJ, Davies SM, et al.: Early anti-thymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transpl 2002, 8: 40–46.

    Article  CAS  Google Scholar 

  32. Arai S, Margolis J, Zahurak M, et al.: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transpl 2002, 8: 155–160.

    Article  Google Scholar 

  33. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O: Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transpl 2001, 15: 147–53.

    Article  CAS  Google Scholar 

  34. Khoury H, Kashyap A, Adkins DR, et al.: Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transpl 2001, 27: 1059–1064.

    Article  CAS  Google Scholar 

  35. Jacobsohn DA: Emerging therapies for graft-versus-host disease. Expert Opin Emerging Drugs 2003, 8: 323–338. Recent review of new agents including false hopes

    Article  CAS  Google Scholar 

  36. Benito AI, Furlong T, Martin PJ, et al.: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transpl 2001, 72: 1924–1928.

    Article  CAS  Google Scholar 

  37. Couriel DR, Hicks K, Saliba R, et al.: Sirolimus (rapamycin) for treatment of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transpl 2003, 9: 67–68.

    Article  Google Scholar 

  38. Cutler C, Li S, Kim HT, et al.: Sirolimus and tacrolimus as graft-vs.-host disease prophylaxis in allogenic stem cell transplantation: the Dana-Farber Cancer Institute experience. Blood 2004, 104[Suppl 1]:346a.

    Google Scholar 

  39. Ho VT, Zahrieh D, Hochberg E, et al.: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation. Blood 2004, 104: 1224–1226.

    Article  PubMed  CAS  Google Scholar 

  40. Srinivasan R, Chakrabarti S, Walsh T, et al.: Improved survival in steroid-refractory acute graft-versus-host disease after non-myeloablative allogenic transplantation using daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124: 777–786.

    Article  PubMed  CAS  Google Scholar 

  41. Weisser M, Goede V, Schiel X, Kolb HJ: Steroid refractory GVHD of the gut can be treated effectively with daclizumab and sirolimus. Blood 2004, 104[Suppl 1]:349a.

    Google Scholar 

  42. Couriel DR, Saliba R, Hicks K, et al.: Tumor necrosis factor alpha blockade for the treatment of steroidrefractory acute GVHD. Blood 2004, 104: 649–654.

    Article  PubMed  CAS  Google Scholar 

  43. Patriarca F, Sperotto A, Damiani D, et al.: Infliximab treatment for steroid-refractory acute graft-versushost disease. Haematologica 2004, 89: 1352–1359.

    PubMed  CAS  Google Scholar 

  44. Marty FM, Lee SJ, Fahey MM, et al.: Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogenic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102: 2768–2776.

    Article  PubMed  CAS  Google Scholar 

  45. Everitt DE: Important drug warning. http:/www.fda.gov/medwatch/SAFETY/2004/ remicade_DHCP_dec04.pdf. Accessed January 15, 2005.

  46. Prezepiorka D, Kernan NA, Ippoliti C, et al.: Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graftversus-host disease. Blood 2000, 95: 83–89.

    Google Scholar 

  47. Willenbacher W, Basara N, Blau IW, et al.: Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001, 112: 820–823.

    Article  PubMed  CAS  Google Scholar 

  48. Lee SJ, Zahrich D, Agura E, et al.: Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104: 1559–1564.

    Article  PubMed  CAS  Google Scholar 

  49. Baudard M, Vincent A, Moreau P, et al.: Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM and PSC transplant patients. Bone Marrow Transpl 2002, 30: 287–295.

    Article  CAS  Google Scholar 

  50. Basara N, Kiehl MG, Blau W, et al.: Mycophenolate mofetil in the treatment of acute and chronic graft-versus-host disease in hematopoietic stem cell transplant patients: four years of experience. Transpl Proc 2001, 33: 2121–2123.

    Article  CAS  Google Scholar 

  51. Kim JG, Sohn SK, Kim DH, et al.: Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogenic stem cell transplant. Eur J Haematol 2004, 73: 56–61.

    Article  PubMed  CAS  Google Scholar 

  52. Barrett AJ, Rezvani K, Solomon S, et al.: New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program) 2003, 350–371.

  53. Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004, 36: 568–584. Good introduction to mesenchymal stem cell clinical uses.

    Article  PubMed  CAS  Google Scholar 

  54. LeBlanc K, Rasmussen I, Sundberg B, et al.: Treatment of severe graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363: 1439–1441.

    Article  Google Scholar 

  55. Frassoni F, Labopin M, Bacigalupo A, et al.: Expanded mesenchymal stem cell (MSC) re-infused with HLA identical HSC transplants reduce acute and chronic graft-versus-host disease: a matched pair analysis. Bone Marrow Transpl 2002, 29[Suppl 1]:S2.

    Google Scholar 

  56. Furlong T, Leisenring W, Storb R, et al.: Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transpl 2002, 8: 206–212.

    Article  CAS  Google Scholar 

  57. Grenix HT, Volc-Platzer B, Kaths P, et al.: Extracorporeal photochemotherapy in the treatment of steroidrefractory acute graft-versus-host disease: a pilot study. Blood 2000, 96: 2426–431.

    Google Scholar 

  58. Lee S, Dorken B, Schmitt D: Extracorporeal photopheresis in graft-versus-host disease: ultraviolet radiation mediates T cell senescence in vivo. Transpl 2004, 78: 484–485.

    Article  Google Scholar 

  59. Messina C, Locateli F, Lanino E, et al.: Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122: 118–127.

    Article  PubMed  CAS  Google Scholar 

  60. Gorgun G, Miller KB, Foss FM: Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002, 100: 941–947.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastro intestinal Medicine and Nutrition, University of Texas MD Anderson Cancer Center, 1515 Holcomb e Bou levard, Unit 436, 77380, Houston, TX, USA

    William A. Ross MD

Authors
  1. William A. Ross MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ross, W.A. Treatment of gastrointestinal acute graft-versus-host disease. Curr Treat Options Gastro 8, 249–258 (2005). https://doi.org/10.1007/s11938-005-0017-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-005-0017-9

Keywords

Search

Navigation